Prime Medicine
PRME
131 hedge funds and large institutions have $188M invested in Prime Medicine in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 17 closing their positions.
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
13% more funds holding
Funds holding: 116 → 131 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8.19% less ownership
Funds ownership: 57.24% → 49.05% (-8.2%)
29% less capital invested
Capital invested by funds: $266M → $188M (-$77.9M)
56% less call options, than puts
Call options by funds: $243K | Put options by funds: $553K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
+$1.52M |
| 2 |
Walleye Capital
New York
|
+$1.04M |
| 3 |
Goldman Sachs
New York
|
+$708K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$643K |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$599K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.34M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$4.14M |
| 3 |
DM
Deerfield Management
New York
|
-$3.47M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.69M |
| 5 |
BlackRock
New York
|
-$2.6M |
PRME Hedge Fund Activity: Q4 2024 in Review
131 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2024, worth a combined $188M — down 29% from $266M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PRME positions and 17 closed out — a net gain of 17 holders — while 39 added to existing stakes and 32 trimmed.
The largest buyer was Westwood Holdings Group, adding an estimated $1.52M. The largest seller was Vanguard Group, cutting an estimated $4.34M.
- 131 institutional investors held Prime Medicine (PRME) as of Q4 2024, up from 116 in Q3 2024.
- Funds reported $188M of Prime Medicine stock for Q4 2024, down 29% quarter-over-quarter.
- 34 funds opened new Prime Medicine positions in Q4 2024 and 17 closed out, a net change of +17 holders.
- The largest Prime Medicine buyer in Q4 2024 was Westwood Holdings Group, an estimated $1.52M added.
- The largest Prime Medicine seller in Q4 2024 was Vanguard Group, an estimated $4.34M sold.
Based on aggregated 13F filings for Q4 2024.